ES8503441A1 - Antibodies having dual specificities, their preparation and uses therefor. - Google Patents
Antibodies having dual specificities, their preparation and uses therefor.Info
- Publication number
- ES8503441A1 ES8503441A1 ES527963A ES527963A ES8503441A1 ES 8503441 A1 ES8503441 A1 ES 8503441A1 ES 527963 A ES527963 A ES 527963A ES 527963 A ES527963 A ES 527963A ES 8503441 A1 ES8503441 A1 ES 8503441A1
- Authority
- ES
- Spain
- Prior art keywords
- antibodies
- preparation
- uses therefor
- polydomas
- target antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000009977 dual effect Effects 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Abstract
Described herein are "polydomas", the product of the fusion of a hybridoma with a B-lymphocyte or another hybridoma. The polydomas produce a hybrid monoclonal antibody having a dual specificity against two different antigenic determinants. Also described are immunodiagnostic and immunotherapeutic processes which utilize the hybrid monoclonal antibodies or other antibodies having a dual specificity. In those processes, one specificity of the antibody is directed against a target antigen and the other against a moiety which permits a diagnosis to be made or which delivers an agent lethal to the target antigen or associated tissue.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36778482A | 1982-04-12 | 1982-04-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES527963A0 ES527963A0 (en) | 1985-02-16 |
ES8503441A1 true ES8503441A1 (en) | 1985-02-16 |
Family
ID=23448582
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES521370A Granted ES521370A0 (en) | 1982-04-12 | 1983-04-11 | A PROCEDURE FOR OBTAINING A POLYDOMA. |
ES527963A Expired ES8503441A1 (en) | 1982-04-12 | 1983-12-12 | Antibodies having dual specificities, their preparation and uses therefor. |
ES533931A Granted ES533931A0 (en) | 1982-04-12 | 1984-07-02 | A PROCEDURE FOR OBTAINING A POLYDOMA |
ES533930A Expired ES8603080A1 (en) | 1982-04-12 | 1984-07-02 | Antibodies having dual specificities, their preparation and uses therefor. |
ES537257A Expired ES8606655A1 (en) | 1982-04-12 | 1984-10-31 | Antibodies having dual specificities, their preparation and uses therefor. |
ES538727A Expired ES8604424A1 (en) | 1982-04-12 | 1984-12-18 | Antibodies having dual specificities, their preparation and uses therefor. |
ES545247A Expired ES8607386A1 (en) | 1982-04-12 | 1985-07-16 | Antibodies having dual specificities, their preparation and uses therefor. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES521370A Granted ES521370A0 (en) | 1982-04-12 | 1983-04-11 | A PROCEDURE FOR OBTAINING A POLYDOMA. |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES533931A Granted ES533931A0 (en) | 1982-04-12 | 1984-07-02 | A PROCEDURE FOR OBTAINING A POLYDOMA |
ES533930A Expired ES8603080A1 (en) | 1982-04-12 | 1984-07-02 | Antibodies having dual specificities, their preparation and uses therefor. |
ES537257A Expired ES8606655A1 (en) | 1982-04-12 | 1984-10-31 | Antibodies having dual specificities, their preparation and uses therefor. |
ES538727A Expired ES8604424A1 (en) | 1982-04-12 | 1984-12-18 | Antibodies having dual specificities, their preparation and uses therefor. |
ES545247A Expired ES8607386A1 (en) | 1982-04-12 | 1985-07-16 | Antibodies having dual specificities, their preparation and uses therefor. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0105360A4 (en) |
JP (2) | JPH0753119B2 (en) |
AT (1) | AT394577B (en) |
AU (1) | AU550486B2 (en) |
CA (1) | CA1213229A (en) |
CH (1) | CH672796A5 (en) |
ES (7) | ES521370A0 (en) |
FI (1) | FI834529A (en) |
GB (4) | GB2128631B (en) |
IT (1) | IT1219778B (en) |
WO (1) | WO1983003679A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3177776B2 (en) * | 1988-09-27 | 2001-06-18 | 武田薬品工業株式会社 | Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs |
US5292668A (en) * | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
IL70686A (en) * | 1983-01-20 | 1988-07-31 | Suntory Ltd | Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0179872B1 (en) * | 1984-04-23 | 1991-06-19 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
NL8501219A (en) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION. |
US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
EP0241907A3 (en) | 1986-04-14 | 1989-09-13 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
FR2604092B1 (en) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
GB8626413D0 (en) * | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
US5053226A (en) * | 1987-07-15 | 1991-10-01 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
EP0308936B1 (en) * | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
GB2218100A (en) * | 1988-03-02 | 1989-11-08 | Erling Sundrehagen | Conjugates for the detection and/or quantification of antigenic substances in body fluids |
US4892824A (en) * | 1988-03-15 | 1990-01-09 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobulins |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
US5582862A (en) | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
JPH02196799A (en) * | 1988-04-08 | 1990-08-03 | Agency Of Ind Science & Technol | Complex of anti-human cancer protein |
US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
IT1235349B (en) * | 1988-12-23 | 1992-06-30 | Biodata Spa | IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5217713A (en) * | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
WO1990012109A1 (en) * | 1989-03-30 | 1990-10-18 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
FR2652004B1 (en) * | 1989-09-21 | 1994-10-28 | Immunotech Partners | NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS. |
CA2075927A1 (en) * | 1990-02-16 | 1991-08-17 | Victor A. Raso | Hybrid reagents capable of selectively releasing molecules into cells |
TW212184B (en) * | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
ES2093778T3 (en) * | 1991-04-26 | 1997-01-01 | Surface Active Ltd | NEW ANTIBODIES AND METHODS FOR USE. |
GB9316369D0 (en) * | 1993-08-06 | 1993-09-22 | Surface Active Ltd | Diagnostic method |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
GB9421468D0 (en) * | 1994-10-18 | 1994-12-07 | Surface Active Ltd | Biosensor |
JP2001515345A (en) * | 1996-09-20 | 2001-09-18 | ザ・ジェネラル・ホスピタル・コーポレイション | Compositions and methods for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
US20020132274A1 (en) | 2001-01-17 | 2002-09-19 | Nevalainen Marja T. | Diagnostic and monitorings methods for cancer |
ATE516818T1 (en) | 2002-07-31 | 2011-08-15 | Seattle Genetics Inc | AURISTATIN CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE |
EP2486933B1 (en) | 2003-11-06 | 2015-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds conjugated with antibodies |
EA200901236A1 (en) | 2004-03-16 | 2009-12-30 | Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | SUBSTITUTED PHENOXY AND PHENYL DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISTURBANCES |
AU2005332660A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
AU2006236225C1 (en) | 2005-04-19 | 2013-05-02 | Seagen Inc. | Humanized anti-CD70 binding agents and uses thereof |
LT1912671T (en) | 2005-07-18 | 2017-12-11 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
ES2523915T5 (en) | 2006-12-01 | 2022-05-26 | Seagen Inc | Variant Target Binding Agents and Uses Thereof |
ZA200904482B (en) | 2007-01-22 | 2010-09-29 | Genentech Inc | Polyelectrolyte precipitation and purification of antibodies |
PL2282773T3 (en) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
EA029818B8 (en) | 2013-03-15 | 2018-09-28 | Займворкс Инк. | Cytotoxic and anti-mitotic compounds and methods of using the same |
WO2015053381A1 (en) * | 2013-10-10 | 2015-04-16 | 幸成 加藤 | Anti-podoplanin antibody |
US11560422B2 (en) | 2013-12-27 | 2023-01-24 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
SG11201702143PA (en) | 2014-09-17 | 2017-04-27 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10618935B2 (en) | 2015-11-03 | 2020-04-14 | Industrial Technology Research Institute | Antibody-drug conjugate (ADC) and method for forming the same |
WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
EP3600443A1 (en) | 2017-03-24 | 2020-02-05 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
AU2019327490A1 (en) * | 2018-08-30 | 2021-03-25 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
KR20220006519A (en) | 2019-05-10 | 2022-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | antibody drug conjugate |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
JP7397996B2 (en) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | antibody drug conjugate |
TW202317190A (en) | 2021-06-29 | 2023-05-01 | 美商思進公司 | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
-
1983
- 1983-04-11 CA CA000425558A patent/CA1213229A/en not_active Expired
- 1983-04-11 ES ES521370A patent/ES521370A0/en active Granted
- 1983-04-12 AU AU15559/83A patent/AU550486B2/en not_active Expired
- 1983-04-12 AT AT0901883A patent/AT394577B/en not_active IP Right Cessation
- 1983-04-12 CH CH6700/83A patent/CH672796A5/de not_active IP Right Cessation
- 1983-04-12 EP EP19830901672 patent/EP0105360A4/en not_active Ceased
- 1983-04-12 GB GB08332646A patent/GB2128631B/en not_active Expired
- 1983-04-12 WO PCT/US1983/000525 patent/WO1983003679A1/en not_active Application Discontinuation
- 1983-04-12 IT IT20548/83A patent/IT1219778B/en active
- 1983-12-09 FI FI834529A patent/FI834529A/en not_active Application Discontinuation
- 1983-12-12 ES ES527963A patent/ES8503441A1/en not_active Expired
-
1984
- 1984-07-02 ES ES533931A patent/ES533931A0/en active Granted
- 1984-07-02 ES ES533930A patent/ES8603080A1/en not_active Expired
- 1984-10-31 ES ES537257A patent/ES8606655A1/en not_active Expired
- 1984-12-18 ES ES538727A patent/ES8604424A1/en not_active Expired
-
1985
- 1985-07-16 ES ES545247A patent/ES8607386A1/en not_active Expired
- 1985-12-09 GB GB08530309A patent/GB2169921B/en not_active Expired
- 1985-12-09 GB GB08530308A patent/GB2168998B/en not_active Expired
- 1985-12-09 GB GB08530310A patent/GB2167086B/en not_active Expired
-
1987
- 1987-01-05 JP JP62000342A patent/JPH0753119B2/en not_active Expired - Lifetime
-
1994
- 1994-02-10 JP JP6016728A patent/JP2562002B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8604424A1 (en) | Antibodies having dual specificities, their preparation and uses therefor. | |
JPS6447378A (en) | Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof | |
JPS6413988A (en) | Hybridoma | |
DK450183D0 (en) | HUMAN MONOCLONE ANTIBODIES AGAINST A BACTERY TOXIN AND THEIR PREPARATION, CONTINUOUS CELL LINES, PRODUCING ANTITOXIN ANTIBODIES, AND ANTIBODIES 'USES | |
IL80231A (en) | Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors | |
DK164510C (en) | HUMAN HYBRIDOM, HUMANT MONOCLONAL ANTIBODY OBTAINED THEREOF, APPLICATION OF SUCH ANTIBODY AND PROCEDURE FOR THE PREPARATION OF SUCH ANTIBODY | |
PH16642A (en) | Complement-fixing monoclonal antibody to human t cells,and methods of preparing same | |
IE800565L (en) | Monoclonal antibodies to human t cells | |
EP0419574A4 (en) | Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same | |
DE3070744D1 (en) | Hybrid cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody | |
DE3485432D1 (en) | MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR MEMBRANE-ASSOCIATED ANTIGENS. | |
AU545181B2 (en) | Hybridoma for producing monoclonal antibodies | |
EP0352722A3 (en) | Adenocarcinoma antigen binding methods and reagents | |
AU545222B2 (en) | Hybridoma for producing monoconal antibodies | |
EP0351045A3 (en) | Monoclonal antibody nuh2 capable of inactivating motility of sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen | |
IL62879A (en) | Monoclonal antibodies,clones producing them,preparation of such antibodies and clones and cytotoxic and immunoassay using such antibodies | |
ES2000615A6 (en) | Monoclonal antibodies against tumour-associated glycoproteins, process for their preparation and their use. | |
IL94912A0 (en) | Monoclonal antibodies involved in alzheimer's disease,hybridomas secreting these monoclonal antibodies,antigen recognized by these antibodies,and their application | |
GR3020387T3 (en) | Ctaa 28a32, the antigen recognized by mca 28a32 | |
ES8401982A1 (en) | Preparation of anti-T-lymphocyte globulin | |
EP0089771A3 (en) | Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 19970303 |